Kengrexal® (cangrelor)
Kengrexal is the first and only intravenous P2Y12 inhibitor providing rapid platelets inhibition during PCI1
Kengrexal is the only P2Y12 inhibitor with:
• Onset within 2 minutes1
• Offset within 1 hour after discontinuation1
• Average elimination half-life of 3–6 minutes1
Indication:
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.1
How Kengrexal works
Kengrexal is the first and only intravenous P2Y12 inhibitor.1 Kengrexal is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. It binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation.
Rapid onset of platelet inhibition within 2 minutes:
- Intravenous administration.
- Direct acting.
Rapid offset within 1 hour1. Reversible, with rapid offset and return of platelet function within 1 hour after discontinuation:
- Patients who need CABG or surgery after PCI can proceed soon after Kengrexal discontinuation.
- Average elimination half-life of 3–6 minutes.
- Metabolism independent of organ function. Consistent pharmacokinetics1 Not influenced by: Age Gender Renal status Hepatic function
Consistent pharmacokinetics1
Not influenced by:
- Age
- Gender
- Renal status
- Hepatic function
Elfabrio® (pegunigalsidas alfa)
Koncentrat till infusionsvätska, lösning 2 mg/ml (Klar och färglös lösning)
10825-01.11.2024
Chiesi on vuonna 1935 perustettu perheomisteinen lääkeyritys. Uskomme innovaatioihin, vastuullisuuteen ja ihmisten empatiaan. Intohimomme on parantaa potilaiden elämänlaatua maailmanlaajuisesti tutkimuksen, kehityksen ja kestävien ratkaisujen avulla.
© 2026 Chiesi Pharma AB omistaa tämän sivuston tekijänoikeudet ja pidättää kaikki oikeudet siihen.